Arcitumomab
Title: Arcitumomab
CAS Registry Number: 154361-48-5
CAS Name: Anti-(human carcinoembryonic antigen) immunoglobulin G1 Fab¢ fragment (mouse monoclonal IMMU-4 g1-chain) disulfide with mouse monoclonal IMMU-4 light chain
Literature References: Murine monoclonal antibody fragment Fab¢ directed against carcinoembryonic antigen (CEA), an antigen expressed by a majority of colorectal cancers and some adenocarcinomas. Radiolabeled form designed for imaging colorectal tumors. Series of articles on purifn and characterization of anti-CEA antibody: F. J. Primus et al., Cancer Res. 43, 679-701 (1983). Prepn of radiolabeled form: D. Shochat et al., EP 336678; eidem, US 5061641 (1989, 1991 both to Immunomedics); and preclinical evaluation: H. J. Hansen et al., Cancer Res. Suppl. 50, 794s (1990). Clinical study of diagnostic use in colorectal immunoscintigraphy: K. Hughes et al., Ann. Surg. 226, 621 (1997); in breast cancer: D. M. Goldenberg et al., Cancer 89, 104 (2000). Review of pharmacology: S. A. Eccles, Curr. Opin. Mol. Ther. 1, 737-744 (1999); of technical prepn and clinical use: D. A. Erb, H. A. Nabi, J. Nucl. Med. Technol. 28, 12-18 (2000).
 
Derivative Type: 99mTc-Labeled form
CAS Registry Number: 154361-49-6
Additional Names: IMMU-4 99mTc Fab¢
Trademarks: CEA-Scan (Immunomedics)
 
Therap-Cat: 99mTc-labeled form as diagnostic aid (radioactive tumor targeting agent).

Others monographs:
tert-Butyl Hypochlorite3-Ethyl-4-picolineTribromoethanolCannabis
Phenoxyacetyl CellulosePhaseolinBunaftineSanguinarine
IophendylateCephapirin SodiumNorgestimateLithium Fluoride
DamascenineTaltirelinLysidineCesium
©2016 DrugLead US FDA&EMEA